Press Releases Year None2020201920182017 Turning Point Therapeutics to Participate in H.C. Wainwright Precision Oncology Investor Conference Sep 21, 2020 Turning Point Therapeutics to Participate in Upcoming Investor Conferences Sep 01, 2020 Turning Point Therapeutics Announces Scientific Advisory Board Aug 31, 2020 Turning Point Therapeutics Granted Fast-Track Designation for Repotrectinib in NTRK-Positive TKI-Pretreated Advanced Solid Tumors Aug 24, 2020 Turning Point Therapeutics Reports Early Interim Data From Registrational Phase 2 Trident-1 Study of Repotrectinib, Provides Regulatory Update Aug 19, 2020 Turning Point Therapeutics Reports Second-Quarter Financial Results, Provides Operational Updates Aug 10, 2020 Turning Point Therapeutics Names Heather Adams as Vice President of Human Resources Jul 27, 2020 Turning Point Therapeutics Names Andrew Partridge As Executive Vice President and Chief Commercial Officer Jul 13, 2020 Turning Point Therapeutics and Zai Lab Announce Exclusive License Agreement For Repotrectinib in Greater China Jul 07, 2020 Turning Point Therapeutics’ Lead Drug Candidate Repotrectinib Increases Effectiveness of KRAS-G12C and MEK Inhibitors in Preclincal KRAS Cancer Models Jun 22, 2020 Pagination Current page 1 Page 2 Page 3 Next page next › Last page last » Displaying 1 - 10 of 27
Turning Point Therapeutics to Participate in H.C. Wainwright Precision Oncology Investor Conference Sep 21, 2020
Turning Point Therapeutics Granted Fast-Track Designation for Repotrectinib in NTRK-Positive TKI-Pretreated Advanced Solid Tumors Aug 24, 2020
Turning Point Therapeutics Reports Early Interim Data From Registrational Phase 2 Trident-1 Study of Repotrectinib, Provides Regulatory Update Aug 19, 2020
Turning Point Therapeutics Reports Second-Quarter Financial Results, Provides Operational Updates Aug 10, 2020
Turning Point Therapeutics Names Andrew Partridge As Executive Vice President and Chief Commercial Officer Jul 13, 2020
Turning Point Therapeutics and Zai Lab Announce Exclusive License Agreement For Repotrectinib in Greater China Jul 07, 2020
Turning Point Therapeutics’ Lead Drug Candidate Repotrectinib Increases Effectiveness of KRAS-G12C and MEK Inhibitors in Preclincal KRAS Cancer Models Jun 22, 2020
